So, more or less, label as expected. No primary indication. Those who are on statins, and still have high LDL/TG/Lpa/ApoB..recommended Rx is anti-PCSK9 because it REDUCE all four bio-marker (MDCO), and supplement that (for those who are LAZY to do something themself) with ATC (people prefer that insurance pay more expensive drug, like Vascepa) good omega-3.
There is no reason why should Rx further go up, as they did in last few months. Is there a way to collect REAL WORLD DATA on those who Rx Vascepa?
Market Data 
Markets 
AI
